Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 9/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280727 | 0.84 | MAPT (0.46) | HDAC2HDAC8HDAC6GLAHSD17B10 | |
| SCHEMBL5078396 | 0.78 | HDAC6 (1.00) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5078399 | 0.78 | HDAC6 (1.00) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5082166 | 0.78 | HDAC6 (1.00) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5077671 | 0.76 | HDAC6 (1.00) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5077668 | 0.76 | HDAC6 (1.00) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5579701 | 0.76 | HDAC6 (0.81) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5579361 | 0.75 | HDAC2 (0.74) | HDAC2HDAC8HDAC6 | |
| SCHEMBL29778116 | 0.74 | HDAC2 (0.49) | HDAC2HDAC8HDAC6LMNAALOX12 | |
| SCHEMBL7057266 | 0.74 | HDAC8 (0.62) | HDAC2HDAC8HDAC6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | claimed |
| EP-1572209-A4 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | MERCK & CO INC (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1572209-A1 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | Merck & Co., Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050166335-A1 | Composition for dyeing keratinous fibers comprising at least one diamino-N,N-dihydropyrazolone derivative | L'OREAL S.A. (FR) | 2005-08-04 | — | — | US | disclosed |
| US-6908921-B2 | Quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004054584-A1 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | MERCK & CO., INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050166335-A1 | Composition for dyeing keratinous fibers comprising at least one diamino-N,N-dihydropyrazolone derivative | KRT18, DAO, AOC1 | HDAC2 1478/4885HDAC8 1524/4885HDAC6 1213/4885 |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | BDKRB1, BDKRB2, LTB4R2 | HDAC2 2455/4885HDAC8 3954/4885HDAC6 4045/4885 |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | BDKRB1, BDKRB2, LTB4R2 | HDAC2 3230/4885HDAC8 4155/4885HDAC6 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.